Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical Inc. has identified several potential upside drivers that could positively influence its financial performance, including accelerated growth in the spine market and increased sales in Enabling Technologies. Although the company's 2Q25 results showed a modest revenue increase of 3.3% to $651 million, this figure was slightly below market expectations of $664 million, highlighting a need for stronger performance in the future. The overall outlook remains positive due to the company's strategic focus on enhancing margins and expanding its revenue streams, particularly in the musculoskeletal solutions segment, which accounts for the majority of its income.

The analysis highlights several fundamental risks contributing to a negative outlook on Globus Medical's stock. Key concerns include slower than expected growth in the spine market, revenue dis-synergies following the NUVA merger, and disappointing sales in Enabling Technologies, which may hinder overall revenue performance. Additionally, projections indicate potential revenue growth slowing to low-single digits, thereby limiting margin expansion and raising concerns about the company's financial trajectory.